Literature DB >> 25107573

Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-α.

Chise Tateno1, Toshinobu Yamamoto2, Rie Utoh3, Chihiro Yamasaki4, Yuji Ishida5, Yuka Myoken6, Ken Oofusa7, Miyoko Okada2, Naohisa Tsutsui2, Katsutoshi Yoshizato8.   

Abstract

Peroxisome proliferator (PP)-activated receptor-α (PPARα) agonists exhibit species-specific effects on livers of the rodent and human (h), which has been considered to reside in the difference of PPARα gene structures. However, the contribution of h-hepatocytes (heps) to the species-specificity remains to be clarified. In this study, the effects of fenofibrate were investigated using a hepatocyte-humanized chimeric mouse (m) model whose livers were replaced with h-heps at >70%. Fenofibrate induced hepatocellular hypertrophy, cell proliferation, and peroxisome proliferation in livers of severe combined immunodeficiency (SCID) mice, but not in the h-hep of chimeric mouse livers. Fenofibrate increased the expression of the enzymes of β- and ω-hydroxylation and deoxygenation of lipids at both gene and protein levels in SCID mouse livers, but not in the h-heps of chimeric mouse livers, supporting the studies with h-PPARα-transgenic mice, a hitherto reliable model for studying the regulation of h-PPARα in the h-liver in most respects, except the induction of the peroxisome proliferation. This study indicates the importance of not only h-PPARα gene but also h-heps themselves to correctly predict effects of fibrates on h-livers, and, therefore, suggests that the chimeric mouse is a currently available, consistent, and reliable model to obtain pharmaceutical data concerning the effects of fibrates on h-livers.
© 2014 by The Author(s).

Entities:  

Keywords:  PPARα; fenofibrate; human hepatocytes; humanized mice

Mesh:

Substances:

Year:  2014        PMID: 25107573     DOI: 10.1177/0192623314544378

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  10 in total

Review 1.  Case examples of an evaluation of the human relevance of the pyrethroids/pyrethrins-induced liver tumours in rodents based on the mode of action.

Authors:  Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2018-01-16       Impact factor: 3.524

2.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

3.  Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.

Authors:  Ravi Rajagopalan; Lin Pan; Caralee Schaefer; John Nicholas; Sharlene Lim; Shawn Misialek; Sarah Stevens; Lisa Hooi; Natalia Aleskovski; Donald Ruhrmund; Karl Kossen; Lea Huang; Sophia Yap; Leonid Beigelman; Vladimir Serebryany; Jyanwei Liu; Srikonda Sastry; Scott Seiwert; Brad Buckman
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 4.  The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.

Authors:  J Christopher Corton; Jeffrey M Peters; James E Klaunig
Journal:  Arch Toxicol       Date:  2017-12-02       Impact factor: 5.153

5.  The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes.

Authors:  Maria Thomas; Christine Bayha; Kathrin Klein; Simon Müller; Thomas S Weiss; Matthias Schwab; Ulrich M Zanger
Journal:  BMC Cancer       Date:  2015-06-30       Impact factor: 4.430

6.  The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice.

Authors:  Montserrat A de la Rosa Rodriguez; Go Sugahara; Guido J E J Hooiveld; Yuji Ishida; Chise Tateno; Sander Kersten
Journal:  BMC Genomics       Date:  2018-06-07       Impact factor: 3.969

7.  Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers.

Authors:  Marie N S Gendy; Patricia Di Ciano; William J Kowalczyk; Sean P Barrett; Tony P George; Stephen Heishman; Bernard Le Foll
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

Review 8.  Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.

Authors:  Joost Boeckmans; Alessandra Natale; Matthias Rombaut; Karolien Buyl; Vera Rogiers; Joery De Kock; Tamara Vanhaecke; Robim M Rodrigues
Journal:  Cells       Date:  2019-12-21       Impact factor: 6.600

9.  Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.

Authors:  Dara L Burdette; Scott Lazerwith; Jenny Yang; Henry L Y Chan; William E Delaney Iv; Simon P Fletcher; Tomas Cihlar; Becket Feierbach
Journal:  PLoS One       Date:  2022-04-01       Impact factor: 3.240

10.  The Peroxisome Proliferator-Activated Receptor α is dispensable for cold-induced adipose tissue browning in mice.

Authors:  Merel Defour; Wieneke Dijk; Philip Ruppert; Emmani B M Nascimento; Patrick Schrauwen; Sander Kersten
Journal:  Mol Metab       Date:  2018-02-09       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.